Routine physicals, nobody enjoys the nasal swab moment. A new device eases one of the most annoying parts of routine physicals: the invasive nasal swab used for flu and COVID-19 tests. A Japanese startup has developed a system that collects samples through breath analysis, eliminating the need for a swab shoved up the nose.

What You Need to Know

The device uses a mouthpiece that captures exhaled particles. Analysis of breath biomarkers can detect respiratory viruses and other conditions. The system is designed for routine clinic use, potentially replacing swab-based collection for many tests. The startup plans to seek regulatory approval in Japan and later expand globally.

How the Breath-Based System Works

Patients simply breathe into a handheld mouthpiece for about 30 seconds. The device captures tiny droplets from the exhaled air and analyzes them for viral RNA or bacterial signatures. The breath sample is then processed in a compact analyzer that delivers results in under 15 minutes. The system requires no special training to operate, making it suitable for busy clinics.

The technology behind the device relies on condensation particle counting combined with biosensor detection. Researchers have validated the method against standard nasal swab PCR tests in early trials, showing comparable accuracy for influenza A and B as well as SARS-CoV-2.

Why This Matters

Nasal swabs have long been a barrier to routine testing. Many patients delay or avoid tests because of the discomfort. The new device could increase testing compliance, particularly for children and elderly patients who find swabs especially unpleasant. For clinics, faster sample collection reduces wait times and staff exposure to respiratory droplets. If the system gains regulatory clearance, it could reshape how doctors screen for respiratory infections during annual physicals and seasonal outbreaks.

Nobody likes getting a swab shoved up their nose. The startup's alternative could remove that hurdle from public health surveillance. The device also reduces medical waste, as it uses no disposable swabs or transport media.

Key Features of the Device

  • Noninvasive sample collection: No swabs, no nasal discomfort. Breath capture is painless and quick.
  • Rapid results: The analyzer returns findings in under 15 minutes, allowing same-visit diagnosis.
  • Portable design: The unit is small enough for a desktop, suitable for small clinics and mobile health units.

Market and Regulatory Path

The Japanese startup has not disclosed its name but is backed by government health innovation grants. The company expects to submit clinical data to Japan's Pharmaceuticals and Medical Devices Agency within the next year. If approved, the device would first target domestic clinics, with plans for CE marking and FDA submission later. The global market for respiratory diagnostics is expected to surpass $15 billion by 2028, and a less invasive option could capture significant share.

Competitors have developed saliva-based tests, but breath analysis offers the advantage of capturing deep lung samples. The startup's approach combines sensitivity with ease of use, potentially making it a standard tool in routine physicals. Most annoying parts of those checkups may soon include one less unpleasant procedure.